Product Liability Lawyers Accepting Morcellator Cancer Lawsuits

Product liability trial lawyers are reviewing claims against the manufacturers of power morcellators due to a failure to warn that the device may cause the spread of unsuspected uterine sarcoma.
 
1 2
Stuart DiMartini
Stuart DiMartini
NEW YORK - Jan. 25, 2015 - PRLog -- New York City personal injury attorney, Stuart DiMartini, announced that his firm, in conjunction with trial lawyers throughout the nation, are reviewing claims surrounding the allegations that the use of a power morcellator used during a hysterectomy or myomectomy in women with unsuspected uterine sarcoma poses a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis significantly worsening the patient’s chance for long-term survival.

A laparoscopic power morcellator is a surgical instrument used during different types of laparoscopic (minimally invasive) surgeries to treat uterine fibroids, including a hysterectomy or myomectomy.

A hysterectomy is the surgical removal of the uterus. It may also involve removal of the cervix, ovaries, fallopian tubes and other surrounding structures.

A myomectomy is the surgical removal of uterine fibroids.

Morcellation refers to the division of tissue into smaller pieces or fragments and is used to facilitate the removal of tissue through a small incision site.

Each year in the United States, approximately 500,000 women undergo a hysterectomy.  A hysterectomy is the second most common surgery among women.

In addition, an estimated 50,000 women undergo uterine fibroid surgery or a myomectomy each year.

According to DiMartini, on April 17, 2014, the Food and Drug Administration (FDA) issued its first a safety communication concerning the use of power morellators during laparoscopic uterine hysterectomy and myomectomy.

The FDA stated: "Because of this risk and the availability of alternative surgical options for most women, the FDA is warning against the use of laparoscopic power morcellators in the majority of women undergoing myomectomy or hysterectomy for treatment of fibroids."

The FDA estimates that 1 in 350 women undergoing a hysterectomy or myomectomy for the treatment of fibroids have unsuspected uterine sarcoma.

DiMartini advises any woman who has developed uterus, pelvis or abdomen cancer after undergoing a laparoscopic hysterectomy or uterine fibroid removal surgery to speak to a product liability lawyer as soon as possible to protect their rights and assert their claim.

# # #

About the Law Office of Stuart DiMartini

Stuart DiMartini is a personal injury lawyer who has been protecting and asserting the rights of the seriously injured since 1987. With offices in New York and in New Jersey, Mr. DiMartini understands the hardships accident victims face and as such has devoted his legal career to representing those seriously injured in accidents throughout the New York City metropolitan area.

morcellator-cancer-lawyers.com/

End
Source:
Email:***@morcellator-cancer-lawyers.com Email Verified
Tags:Stuart DiMartini, Morcellator, Cancer, Lawyer, Attorney
Industry:Legal
Location:New York City - New York - United States
Subject:Projects
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jan 25, 2015